HOME > TOP STORIES

TOP STORIES

REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs

December 12, 2011
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development

December 9, 2011
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs

December 8, 2011
BUSINESS Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals

December 7, 2011
BUSINESS Growth for All Products Is Indispensable: President Alvarez of MSD

December 7, 2011
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years

December 7, 2011
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales

December 6, 2011
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”

December 6, 2011
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut

December 5, 2011
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report

December 2, 2011
BUSINESS UK AstraZeneca CEO Brennan Says Investment in Japan, a “Very Important Market,” Will Continue

December 1, 2011
REGULATORY CSIMC Approves Outline of Plan to Promote Generic Drug Use

December 1, 2011
REGULATORY CSIMC Expert Member Yoshimura Says Conditions Must Improve to Promote Generics

November 30, 2011
BUSINESS AZ to Bolster Its Top Position in Breast Cancer Area

November 29, 2011
REGULATORY Record 101 Generics from 30 Companies Listed for Aricept

November 29, 2011
REGULATORY MHLW Says Sept Drug Price Settlement Rate Dips to 78.1%, Falling Below 2009 Level

November 28, 2011
REGULATORY CSIMC to Discuss Additional Price Cuts for Long-Listed Drugs

November 28, 2011
ORGANIZATION Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ

November 28, 2011
REGULATORY DPJ's Subcommittee for PAL Amendment Begins Deliberations Nov. 28, to Compile Opinion by End-Jan

November 25, 2011
ORGANIZATION MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise

November 25, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…